Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer

Regeneron Announces Appointment of Robert E. Landry as Senior Vice President,
                     Finance and Chief Financial Officer

PR Newswire

TARRYTOWN, N.Y., Sept. 10, 2013

TARRYTOWN, N.Y., Sept.10, 2013 /PRNewswire/ --Regeneron Pharmaceuticals,
Inc. (NASDAQ: REGN) today announced the appointment of Robert E. Landry as
Senior Vice President, Finance. Mr. Landry will also assume the position of
Chief Financial Officer of Regeneron on October 1. After 18 years as CFO,
Murray A. Goldberg will transition to a new role as Senior Vice President,
Administration in anticipation of his retirement at the end of 2014.

Mr. Landry brings over two decades of varied financial and operating
experience in the global pharmaceutical industry, most recently as Senior Vice
President and Treasurer of Pfizer, Inc. He will report to Leonard S.
Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.
Mr. Landry will have responsibility for all financial functions, including
Controller's, Treasury, Financial Planning, Tax, and Internal Audit. In his
new role, Mr. Goldberg will continue to have responsibility for Alliance
Management and various administrative functions.

"Murray has been an integral member of the Regeneron senior management team
for close to two decades and his contribution to our success as we grew from a
development stage biotechnology company to one of the largest biotechnology
companies in the world has been invaluable. We are extremely fortunate that
Murray will stay at Regeneron through 2014 to help us with the transition to a
new CFO," said Dr. Schleifer. "Bob Landry brings with him a breadth of
domestic and international financial expertise at Pfizer and Wyeth. We look
forward to the valuable perspective he will bring, as we continue to expand
our operations in the U.S. and globally."

"I am pleased to be able to join an organization that is known for its deep
commitment to science and to bringing life changing medicines to patients,"
said Robert Landry. "I am excited about this opportunity and look forward to
working with the talented Regeneron management team."

Prior to serving as Senior Vice President and Treasurer of Pfizer, Mr. Landry
held a variety of U.S. and international financial and general management
positions at Wyeth and Pfizer including Senior Vice President – Finance,
Pfizer's Diversified Businesses, Treasurer of Wyeth, Director of Sales and
Marketing and Chief Financial Officer for Wyeth Pharmaceuticals' Australian
and New Zealand affiliates, and various other assignments in both the
pharmaceuticals business and the parent company. Mr. Landry joined Wyeth
after spending two years as an auditor with PricewaterhouseCoopers LLP. He
holds a B.B.A in Accounting from the University of Notre Dame.

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in
Tarrytown, New York that discovers, invents, develops, manufactures, and
commercializes medicines for the treatment of serious medical conditions.
Regeneron markets medicines for eye diseases, colorectal cancer, and a rare
inflammatory condition and has product candidates in development in other
areas of high unmet medical need, including hypercholesterolemia, oncology,
rheumatoid arthritis, allergic asthma, and atopic dermatitis. For additional
information about the company, please visit www.regeneron.com.

Contact Information:
Manisha Narasimhan, Ph.D.          Peter Dworkin
Investor Relations  Corporate
                                                                         Communications
914.847.5126 914.847.7640 
manisha.narasimhan@regeneron.com                     peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

Website: http://www.regeneron.com